Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT04621864 |
Other study ID # |
MRC-01-18-270 |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
November 20, 2020 |
Est. completion date |
December 31, 2022 |
Study information
Verified date |
November 2021 |
Source |
Hamad Medical Corporation |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
Variation of morphine requirements are seen considerably. Studies showed that
pharmacogenetics (PGx) could possibly be used to tailor pain medication according to an
individual's genetic background. While prior studies demonstrated the association of genetic
polymorphism with opioid requirements in various types of surgeries in Asian and European
populations, there are no published data in Middle East populations especially Arabs.
However, in our area we have a lot of theincity that may give us an answer for this research
question.
Objectives: The primary Objective of this study is to investigate whether the genetic
polymorphism of human μ-opioid receptor gene (OPRM1), ATP binding cassette gene (ABCB1) and
rs2952768 are contributing to the variation of morphine consumption in women undergoing
laparoscopic cholecystectomy. The secondary objective is to assess the effect of these
genetic polymorphisms on pain score, analgesic dosage requirements, and complications of
morphine use in these patients within the first 24 hours.
Description:
Background: Variation of morphine requirements are seen considerably. Studies showed that
pharmacogenetics (PGx) could possibly be used to tailor pain medication according to an
individual's genetic background. While prior studies demonstrated the association of genetic
polymorphism with opioid requirements in various types of surgeries in Asian and European
populations, there are no published data in Middle East populations especially Arabs.
Objectives: The primary Objective of this study is to investigate whether the genetic
polymorphism of human μ-opioid receptor gene (OPRM1), ATP binding cassette gene (ABCB1) and
rs2952768 are contributing to the variation of morphine consumption in women undergoing
laparoscopic cholecystectomy. The secondary objective is to assess the effect of these
genetic polymorphisms on pain score, analgesic dosage requirements, and complications of
morphine use in these patients within the first 24 hours.
Methods: This is a pilot prospective cohort study to be conducted at Al-Wakrah Hospital, HMC
after receiving IRB approval from MRC. The aim is to recruit 100 adult female Arab patients
with American Society of Anesthesiologists physical status of I or II in whom planned
postoperative pain management by morphine will be requested after laparoscopic
cholecyctectomy Baseline demographic information will be collected at baseline along with 4ml
blood sample for genotyping. Morphine will be administered repeatedly for postoperative pain
relief and the total dose administered within the first 24 hours will be collected. The
analgesic effect will be evaluated using a visual analogue scale (VAS). Multiple linear
regression will be used to evaluate the association of the genetic variant groups with the
morphine dose and the pain score after adjusting for different confounders. Logistic
regression will be used to evaluate the association of side effect of vomiting and
respiratory depression with the genetic variants. Baseline characteristic values will be
reported as mean ± SD for continuous variables or frequency and percentage for categorical
variables. A priori P value of ≤ 0.05 will be considered significant. All analyses will be
done using the Statistical version 25 of SPSS software.